Could Tai-Chi ease chemo fatigue? new trial investigates
NCT ID NCT07702409
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This trial tests whether practicing Tai-Chi can help reduce fatigue in breast cancer patients receiving chemotherapy. Participants are randomly assigned to either routine care alone or routine care plus Tai-Chi practice five times a week for three weeks. Fatigue levels are measured every three days to see if the gentle exercise makes a difference.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Tai-Chi exercise (18 forms of Tai-Chi shibashi adapted from Yang's style)
- What this could lead to
- If it works, this could offer a simple, drug-free way to ease fatigue during chemotherapy for breast cancer patients.
- What could go wrong
- This is a small, early trial with 61 participants, and the lack of blinding may bias results. The benefit may be modest or not generalizable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
61 people
The number who actually took part.
- Started
-
Mar 2026
- Finished
-
Jun 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 64 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The inclusion criteria for the study sample were conscious and cooperative patients (compos mentis), patients with a good condition, breast cancer patients undergoing chemotherapy, aged 18-64 years, stage 0-III, having an electronic cell phone or laptop, and willing to participate. Exclusion Criteria: * The exclusion criteria in this study were patients with mental illness or severe cognitive impairment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dharmais Cancer Hospital
Jakarta, Jakarta Special Capital Region, 11420, Indonesia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Retrospective analysis of pyrotinib in the treatment of HER2-Positive advanced breast cancer previously treated with trastuzumab and pertuzumab
- Mind and body: does resilience leave a molecular mark in breast cancer?
- Which pain block works better for breast surgery?
- Can a Triple-Drug combo erase HER2-Positive breast tumors before surgery?
- Bacteria inside tumors may hold the key to breast cancer treatment
- Can a newer drug ease the bone pain of chemotherapy support?